Description
Glyxambi is a fixed-dose combination medication containing 5 mg of linagliptin and 10 mg of empagliflozin. It is prescribed to adults with type 2 diabetes mellitus to improve blood sugar control, alongside diet and exercise. Linagliptin is a DPP-4 inhibitor that enhances insulin secretion and reduces glucagon levels, particularly after meals. Empagliflozin is an SGLT2 inhibitor that increases glucose excretion through urine. Together, they help lower blood glucose levels and may reduce the risk of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.
.jpg)
Change Language